Comparison
Abducens Nerve Neoplasm C1263898 vs 17q12 Recurrent Deletion Syndrome C6011081
Clinical comparison between Abducens Nerve Neoplasm and 17q12 Recurrent Deletion Syndrome for differential diagnosis and treatment planning.
Abducens Nerve Neoplasm C1263898
A tumor of the 6th cranial nerve that controls eye movement. Can affect anyone. Treated with surgery or radiation.
17q12 Recurrent Deletion Syndrome C6011081
A genetic condition from deletion on chromosome 17. Can involve developmental delays, neurological features, and potential kidney involvement. Management requires regular monitoring and supportive therapies.
6 comparison axes
Onset
Abducens Nerve Neoplasm C1263898
Variable
17q12 Recurrent Deletion Syndrome C6011081
0-null
Onset patterns differ
Severity
Abducens Nerve Neoplasm C1263898
severe
17q12 Recurrent Deletion Syndrome C6011081
moderate
Different severity levels
Chronic
Abducens Nerve Neoplasm C1263898
Chronic
17q12 Recurrent Deletion Syndrome C6011081
Chronic
Differing course
Communicable
Abducens Nerve Neoplasm C1263898
No
17q12 Recurrent Deletion Syndrome C6011081
No
Different transmission
Body System
Abducens Nerve Neoplasm C1263898
neurologic
17q12 Recurrent Deletion Syndrome C6011081
congenital
Same/different system
Category
Abducens Nerve Neoplasm C1263898
oncology
17q12 Recurrent Deletion Syndrome C6011081
genetic
Different category
Bottom line
abducens-nerve-neoplasm-C1263898 and 17q12-recurrent-deletion-syndrome-C6011081 differ in severity, etiology
Key differentiating points
Findings that most reliably separate the two conditions at the bedside or in the workup.
| Feature | Abducens Nerve Neoplasm C1263898 | 17q12 Recurrent Deletion Syndrome C6011081 | Discriminating power |
|---|---|---|---|
| Eye movement | May impair lateral gaze or cause double vision, but findings can vary. | Sixth-nerve palsy is not a supplied defining feature; neurologic features may be broader. | High |
| Development | Developmental delay is not described as a core feature. | Developmental delay may occur and can prompt genetic evaluation. | High |
| Kidney involvement | Kidney disease is not part of the supplied description. | Potential kidney involvement is described and may require monitoring. | Moderate |
When to favor each condition
Choose Abducens Nerve Neoplasm C1263898 when
Progressive eye-movement problem suggesting sixth-nerve involvement
A focal neurologic process fits the supplied tumor description better than a multisystem genetic syndrome.
Moderate
Imaging raises concern for a cranial-nerve mass
Specialist assessment can determine whether oncology evaluation is appropriate.
Moderate
No congenital or developmental pattern is evident
Variable-onset focal disease is more consistent with the left concept, but this does not confirm it.
Low
Choose 17q12 Recurrent Deletion Syndrome C6011081 when
Early developmental concerns with possible multisystem features
This pattern aligns better with a congenital genetic condition.
Moderate
Kidney abnormalities accompany neurodevelopmental findings
Potential renal involvement is specifically mentioned for the deletion syndrome.
Moderate
Family or clinician suspects a chromosomal disorder
Genetic testing, not tumor treatment, is the relevant next consideration.
High
How key tests differ
| Test | Abducens Nerve Neoplasm C1263898 | 17q12 Recurrent Deletion Syndrome C6011081 | Interpretation |
|---|---|---|---|
| Brain and cranial-nerve MRI | May show a lesion near the sixth nerve; histology is not established by imaging alone. | No specific nerve tumor is expected from the supplied description. | A mass supports further oncology assessment; its absence does not exclude all neurologic disease. |
| Chromosomal microarray or targeted genetic testing | Not expected to establish the nerve neoplasm. | May identify a recurrent 17q12 deletion when clinically suspected. | A confirmed deletion supports the syndrome; interpretation requires a genetics clinician. |
| Renal evaluation | Not routinely indicated by the supplied tumor description. | Ultrasound or laboratory monitoring may be considered because kidney involvement is possible. | Abnormal kidney results are findings requiring clinician review, not a complete diagnosis. |
Prognosis comparison
Abducens Nerve Neoplasm C1263898
- Outcome
- Potentially serious chronic neurologic or oncologic course; exact outcome is not established.
- Factors
- Tumor behavior, neurologic effects, and response to specialist treatment may influence course.
17q12 Recurrent Deletion Syndrome C6011081
- Outcome
- Usually a lifelong genetic condition with variable developmental and possible renal effects.
- Factors
- Extent of developmental needs, neurologic features, and kidney involvement may affect outlook.
Time frame: Both may be chronic; precise onset and survival data are not supplied.
Individual prognosis requires clinician interpretation and should not be inferred from severity labels alone.
Complications comparison
| Complication | Presentation |
|---|---|
| Visual function problems | Double vision, strabismus, or reduced eye movement may occur. Specific eye-movement complications are not established in the supplied data. Ophthalmology assessment is appropriate when visual symptoms are present. |
| Treatment-related burden | Surgery or radiation may be considered after confirmation, with procedure-specific risks. Management is generally monitoring and supportive therapy rather than tumor-directed treatment. No treatment doses or protocols are established here. |
| Renal complications | Not described in the supplied source. Possible kidney involvement may need long-term surveillance. The frequency and severity are not established by these data. |
Patient education highlights
- HighDifferent causes
One is a possible cranial-nerve tumor; the other is a genetic deletion syndrome. They are not interchangeable diagnoses.
- HighConfirmation
Imaging, genetic testing, and specialist review may be needed. An abnormal result alone does not establish the full diagnosis.
- MediumMonitoring
Report new vision changes, developmental concerns, or urinary and kidney symptoms promptly for clinician assessment.